<DOC>
	<DOCNO>NCT00923299</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving cetuximab together trastuzumab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose trastuzumab give together cetuximab see well work treat patient metastatic pancreatic cancer progress previous treatment gemcitabine .</brief_summary>
	<brief_title>Cetuximab Trastuzumab Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend dose trastuzumab give cetuximab patient metastatic pancreatic cancer progress gemcitabine-based chemotherapy . ( Phase I ) - Evaluate objective response rate assess RECIST criterion . ( Phase II ) Secondary - Evaluate safety profile assess NCI CTCAE v3.0 . - Evaluate progression-free survival . - Evaluate overall survival . OUTLINE : This multicenter , phase I dose-escalation study trastuzumab follow phase II study . Patients receive cetuximab IV 1-2 hour trastuzumab IV 30-90 minute day 1 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma pancreas Progressed firstline adjuvant gemcitabinebased chemotherapy Measurable disease assess RECIST criterion No known brain metastasis symptomatic carcinomatous leptomeningitis PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy ≥ 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 2.5 time ULN ALT/AST ≤ 5 time ULN LVEF ≥ 55 % Not pregnant nursing Fertile patient must use effective contraception No significant comorbidities , include follow : Cardiovascular disease Documented history congestive heart failure Uncontrolled , highrisk arrhythmia Angina pectoris require treatment Clinically significant valvular disease Evidence transmural myocardial infarction ECG Uncontrolled hypertension Active bleeding Clinically significant active infection Severe dyspnea rest Oxygendependency No malignancy except basal cell carcinoma skin No severe hypersensitivity cetuximab trastuzumab No medical psychological condition would preclude study completion give informed consent No legal incapacity limited legal capacity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior cetuximab trastuzumab No concurrent experimental drug anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>